Skip to main content

Table 1 Baseline demographic and clinical characteristics

From: Onset of efficacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia: post hoc analysis of a randomized, double-blind clinical trial

Baseline demographics/patient characteristics

Placebo,

n = 83

Paliperidone palmitate

  

234/39 mg, n = 72

234/156 mg, n = 72

234/234 mg, n = 85

Age in years, mean (SD)

40.3 (11.2)

40.1 (10.2)

38.4 (10.6)

39.0 (11.0)

Sex, n (%)

   Male

56 (67.5)

50 (69.4)

47 (65.3)

60 (70.6)

   Female

27 (32.5)

22 (30.6)

25 (34.7)

25 (29.4)

Race, n (%)

   Caucasian

39 (47.0)

40 (55.6)

35 (48.6)

40 (47.1)

   African American

36 (43.4)

24 (33.3)

26 (36.1)

35 (41.2)

   Asian

8 (9.6)

5 (6.9)

10 (13.9)

6 (7.1)

   Other

0 (0)

3 (4.2)

1 (1.4)

4 (4.7)

Age at diagnosis in years, mean (SD)

24.9 (8.1)

24.2 (6.8)

25.8 (8.7)

24.3 (8.0)

Baseline PANSS total score, mean (SD)

92.6 (9.2)

95.8 (8.9)

94.5 (7.9)

96.0 (9.2)

Baseline CGI-S score, n (%)

   Marked (= 5)

73 (88.0)

60 (83.3)

68 (94.4)

74 (87.1)

   Severe (≥6)

10 (12.1)

12 (16.7)

4 (5.6)

11 (12.9)

Prior hospitalization for psychosis, n (%)

   None

5 (6.0)

5 (6.9)

6 (8.3)

7 (8.2)

   1

19 (22.9)

10 (13.9)

9 (12.5)

11 (12.9)

   2

16 (19.3)

13 (18.1)

18 (25.0)

17 (20.0)

   3

9 (10.8)

12 (16.7)

13 (18.1)

12 (14.1)

   ≥4

34 (41.0)

32 (44.4)

26 (36.1)

38 (44.7)

Disposition

   Completed, n (%)

32 (38.6)

35 (48.6)

36 (50.0)

43 (50.6)

   Discontinued, n (%)

51 (61.5)

37 (51.4)

36 (50.0)

42 (49.4)

Reasons for discontinuation

Lack of efficacy

24 (28.9)

16 (22.2)

14 (19.4)

14 (16.5)

Withdrew consent

14 (16.9)

10 (13.9)

11 (15.3)

21 (24.7)

Adverse event

7 (8.4)

6 (8.3)

7 (9.7)

5 (5.9)

Lost to follow-up

4 (4.8)

5 (6.9)

3 (4.2)

1 (1.2)

Other

2 (2.4)

0 (0)

1 (1.4)

1 (1.2)

  1. Each paliperidone palmitate subject received 234 mg of paliperidone palmitate on day 1 and then their assigned dose day 8 and monthly thereafter.
  2. CGI-S = Clinical Global Impression-Severity scale; PANSS = Positive and Negative Syndrome Scale.